OncoZenge AB (publ) (STO:ONCOZ)
Sweden · Delayed Price · Currency is SEK 6.35
+0.49 (8.36%)
Mar 4, 2026, 3:23 PM CET
OncoZenge AB Revenue
In the year 2025, OncoZenge AB had annual revenue of 2.78M SEK with 278,300.00% growth. OncoZenge AB had revenue of 1,000.00 in the quarter ending December 31, 2025.
Revenue
2.78M
Revenue Growth
+278,300.00%
P/S Ratio
32.04
Revenue / Employee
2.78M
Employees
1
Market Cap
89.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.78M | 2.78M | 278,300.00% |
| Dec 31, 2024 | 1,000.00 | -2.00K | -66.67% |
| Dec 31, 2023 | 3.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xbrane Biopharma AB | 152.35M |
| Alzinova AB | 26.12M |
| Scandinavian ChemoTech AB | 12.29M |
| Biovica International AB | 9.89M |
| Spago Nanomedical AB | 4.82M |
| Alligator Bioscience AB | 4.42M |
| Simris Group AB (PUBL) | 3.40M |
| Biosergen AB | 2.09M |